-
Therapeutic area variability in the collection of data supporting protocol end points and objectives
Kenneth Getz & Stella Stergiopoulos
Clinical Trail Methodology: Clinical Investigation
-
Therapeutic area variability in the collection of data supporting protocol end points and objectives
Kenneth Getz & Stella Stergiopoulos
Clinical Trail Methodology: Clinical Investigation
-
Therapeutic area variability in the collection of data supporting protocol end points and objectives
Kenneth Getz & Stella Stergiopoulos
Clinical Trail Methodology: Clinical Investigation
-
Therapeutic area variability in the collection of data supporting protocol end points and objectives
Kenneth Getz & Stella Stergiopoulos
Clinical Trail Methodology: Clinical Investigation
-
Therapeutic area variability in the collection of data supporting protocol end points and objectives
Kenneth Getz & Stella Stergiopoulos
Clinical Trail Methodology: Clinical Investigation
-
Therapeutic area variability in the collection of data supporting protocol end points and objectives
Kenneth Getz & Stella Stergiopoulos
Clinical Trail Methodology: Clinical Investigation
-
Therapeutic area variability in the collection of data supporting protocol end points and objectives
Kenneth Getz & Stella Stergiopoulos
Clinical Trail Methodology: Clinical Investigation
-
Therapeutic area variability in the collection of data supporting protocol end points and objectives
Kenneth Getz & Stella Stergiopoulos
Clinical Trail Methodology: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Talya Waldman, Chrisandra L Shufelt, Glenn D Braunstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Talya Waldman, Chrisandra L Shufelt, Glenn D Braunstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Talya Waldman, Chrisandra L Shufelt, Glenn D Braunstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Talya Waldman, Chrisandra L Shufelt, Glenn D Braunstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Talya Waldman, Chrisandra L Shufelt, Glenn D Braunstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Talya Waldman, Chrisandra L Shufelt, Glenn D Braunstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Talya Waldman, Chrisandra L Shufelt, Glenn D Braunstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Talya Waldman, Chrisandra L Shufelt, Glenn D Braunstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Early vascular aging syndrome: background and proposed definitions
Peter Nilsson
Therapeutic Prospective: Clinical Investigation
-
Novel agents in Waldenstrom macroglobulinemia
Ghayas C Issa, Irene M Ghobrial, Aldo M Roccaro
Therapeutic Prospective: Clinical Investigation
-
Novel agents in Waldenstrom macroglobulinemia
Ghayas C Issa, Irene M Ghobrial, Aldo M Roccaro
Therapeutic Prospective: Clinical Investigation
-
Novel agents in Waldenstrom macroglobulinemia
Ghayas C Issa, Irene M Ghobrial, Aldo M Roccaro
Therapeutic Prospective: Clinical Investigation
-
Novel agents in Waldenstrom macroglobulinemia
Ghayas C Issa, Irene M Ghobrial, Aldo M Roccaro
Therapeutic Prospective: Clinical Investigation
-
Novel agents in Waldenstrom macroglobulinemia
Ghayas C Issa, Irene M Ghobrial, Aldo M Roccaro
Therapeutic Prospective: Clinical Investigation
-
Novel agents in Waldenstrom macroglobulinemia
Ghayas C Issa, Irene M Ghobrial, Aldo M Roccaro
Therapeutic Prospective: Clinical Investigation
-
Novel agents in Waldenstrom macroglobulinemia
Ghayas C Issa, Irene M Ghobrial, Aldo M Roccaro
Therapeutic Prospective: Clinical Investigation
-
Novel agents in Waldenstrom macroglobulinemia
Ghayas C Issa, Irene M Ghobrial, Aldo M Roccaro
Therapeutic Prospective: Clinical Investigation